novel precision drugs that target the tumor microenvironment
These Basque scientists are dedicated to researching tumors for which there is no cure
Publicado en El Confidencial 27-11-2024
BIO 2024 SAN DIEGO
We are pleased to announce that Oncomatryx Biopharma will be attending BIO 2024 in San Diego from June 3-6. We look forward to connecting with biotech leaders and exploring
BIOEQUITY DONOSTI (SPAIN) 2024
From May 12-14 May Oncomatryx Biopharma will be attending BioEquity Europe 2024 in Donosti – San Sebastian We hope to meet you at BioEquity and make the most of
Oncomatryx acquires Austrian company to consolidate its tumour microenvironment drugs
Publicada en el Diario Vasco el 23-05-2023
Basque Country Lehendakari´s visit
Iñigo Urkullu ha visitado la empresa biofarmacéutica Oncomatryx, desarrolladora de tratamientos personalizados para atacar los tumores invasivos Osakidetza, a través de Onkologikoa, formará parte de un ensayo clínico de cáncer con metástasis
“I declare war on cancer stroma”
LAUREANO SIMON, Oncomatryx CEO, declares war on tumor microenvironment. “We envision a new era where cancer in general and invasive tumors in particular will be beaten with orchestrated combinations of precision
Clinical Trial
Published by Deia 2022 – 05 -23
Oncomatryx Capital increase 2022
Published by EXPANSIÓN 2022-03-08 Oncomatryx has carried out a capital increase of 15 million euros to start clinical trials with people with invasive tumors in Spain and the USA.
Bizkaia Impacto Social 2022 Award
Published by El Correo 2022-03-07. Oncomatryx Biopharma, S.L. has been honoured with the 2022 Bizkaia Social Impact Award (Premio Impacto Social 2022) by BBK and EL CORREO at the Sustainable Competitiveness Awards
PEGS Europe Virtual Summit 2020
12 Annual PEGS Europe Virtual Summit 2020 9 Nov – 12 Nov 2020 Myriam Fabre, PhD. (Oncomatryx R&D Director) will attend the virtual conference as a speaker on next Tuesday